Juniper Pharma (JNP) to Discontinue Development of COL-1077 After Phase 2b Trial Fails
Tweet Send to a Friend
Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) today announced that a recently completed Phase 2b clinical trial evaluating its 10% lidocaine bioadhesive ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
